Francis M J, Hastings G Z, Brown A L, Grace K G, Rowlands D J, Brown F, Clarke B E
Department of Virology, Wellcome Biotechnology Ltd., Beckenham, Kent, United Kingdom.
Proc Natl Acad Sci U S A. 1990 Apr;87(7):2545-9. doi: 10.1073/pnas.87.7.2545.
The immunogenicity of a 19 amino acid peptide from foot-and-mouth disease virus has previously been shown to approach that of the inactivated virus from which it was derived after multimeric particulate presentation as an N-terminal fusion with hepatitis B core antigen. In this report we demonstrate that rhinovirus peptide-hepatitis B core antigen fusion proteins are 10-fold more immunogenic than peptide coupled to keyhole limpet hemocyanin and 100-fold more immunogenic than uncoupled peptide with an added helper T-cell epitope. The fusion proteins can be readily administered without adjuvant or with adjuvants acceptable for human and veterinary application and can elicit a response after nasal or oral dosing. The fusion proteins can also act as T-cell-independent antigens. These properties provide further support for their suitability as presentation systems for "foreign" epitopes in the development of vaccines.
此前已表明,口蹄疫病毒的一种19个氨基酸的肽在作为与乙肝核心抗原的N端融合体进行多聚体颗粒呈递后,其免疫原性接近其所衍生的灭活病毒。在本报告中,我们证明鼻病毒肽-乙肝核心抗原融合蛋白的免疫原性比偶联到钥孔戚血蓝蛋白上的肽高10倍,比添加了辅助性T细胞表位的未偶联肽高100倍。融合蛋白无需佐剂或使用人用和兽用可接受的佐剂即可轻松给药,经鼻或口服给药后可引发反应。融合蛋白还可作为不依赖T细胞的抗原。这些特性进一步支持了它们作为疫苗开发中“外来”表位呈递系统的适用性。